Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 208

1.

Lysophosphatidic Acid Signaling in Diabetic Nephropathy.

Lee JH, Kim D, Oh YS, Jun HS.

Int J Mol Sci. 2019 Jun 11;20(11). pii: E2850. doi: 10.3390/ijms20112850. Review.

2.

Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease.

Li AA, Ahmed A, Kim D.

Gut Liver. 2019 Jun 17. doi: 10.5009/gnl19069. [Epub ahead of print]

3.

Pre-Operative Delta-MELD is an Independent Predictor of Higher Mortality following Liver Transplantation.

Cholankeril G, Li AA, Dennis BB, Gadiparthi C, Kim D, Toll AE, Maliakkal BJ, Satapathy SK, Nair S, Ahmed A.

Sci Rep. 2019 Jun 5;9(1):8312. doi: 10.1038/s41598-019-44814-y.

4.

Hepatocellular carcinoma is leading in cancer-related disease burden among hospitalized baby boomers.

Gadiparthi C, Yoo ER, Are VS, Charilaou P, Kim D, Cholankeril G, Pitchumoni C, Ahmed A.

Ann Hepatol. 2019 May 21. pii: S1665-2681(19)30343-6. doi: 10.1016/j.aohep.2019.04.014. [Epub ahead of print]

5.

Nonalcoholic steatohepatitis is associated with a higher risk of advanced colorectal neoplasm.

Cho Y, Lim SK, Joo SK, Jeong DH, Kim JH, Bae JM, Park JH, Chang MS, Lee DH, Jung YJ, Kim BG, Kim D, Lee KL, Kim W.

Liver Int. 2019 Jun 4. doi: 10.1111/liv.14163. [Epub ahead of print]

PMID:
31162812
6.

Economic burden and healthcare utilization in nonalcoholic fatty liver disease.

Yoo ER, Ahmed A, Kim D.

Hepatobiliary Surg Nutr. 2019 Apr;8(2):181-183. doi: 10.21037/hbsn.2018.12.11. No abstract available.

7.

Nonalcoholic fatty liver disease in the over-60s: Impact of sarcopenia and obesity.

Wijarnpreecha K, Panjawatanan P, Aby E, Ahmed A, Kim D.

Maturitas. 2019 Jun;124:48-54. doi: 10.1016/j.maturitas.2019.03.016. Epub 2019 Mar 25. Review.

PMID:
31097179
8.

Trends in hospitalizations for chronic liver disease-related liver failure in the United States, 2005-2014.

Kim D, Cholankeril G, Li AA, Kim W, Tighe SP, Hameed B, Kwo PY, Harrison SA, Younossi ZM, Ahmed A.

Liver Int. 2019 May 13. doi: 10.1111/liv.14135. [Epub ahead of print]

PMID:
31081997
9.

Trends in overall, cardiovascular and cancer-related mortality among individuals with diabetes reported on death certificates in the United States between 2007 and 2017.

Kim D, Li AA, Cholankeril G, Kim SH, Ingelsson E, Knowles JW, Harrington RA, Ahmed A.

Diabetologia. 2019 Jul;62(7):1185-1194. doi: 10.1007/s00125-019-4870-9. Epub 2019 Apr 22.

PMID:
31011776
10.

Genetic Factors Account for Some Disparities in Nonalcoholic Fatty Liver Disease Among Hispanic Subgroups.

Yoo ER, Ahmed A, Kim D.

Clin Gastroenterol Hepatol. 2019 Apr 19. pii: S1542-3565(19)30424-0. doi: 10.1016/j.cgh.2019.04.034. [Epub ahead of print] No abstract available.

PMID:
31009797
11.

Elevated urinary bisphenol A levels are associated with non-alcoholic fatty liver disease among adults in the United States.

Kim D, Yoo ER, Li AA, Cholankeril G, Tighe SP, Kim W, Harrison SA, Ahmed A.

Liver Int. 2019 Mar 29. doi: 10.1111/liv.14110. [Epub ahead of print]

PMID:
30924602
12.

The Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver Disease.

Iqbal U, Perumpail BJ, Akhtar D, Kim D, Ahmed A.

Medicines (Basel). 2019 Mar 18;6(1). pii: E41. doi: 10.3390/medicines6010041. Review.

13.

Associations between sarcopenia and nonalcoholic fatty liver disease and advanced fibrosis in the USA.

Wijarnpreecha K, Kim D, Raymond P, Scribani M, Ahmed A.

Eur J Gastroenterol Hepatol. 2019 Mar 18. doi: 10.1097/MEG.0000000000001397. [Epub ahead of print]

PMID:
30888971
14.

Highly Conductive Paper/Textile Electrodes Using Ligand Exchange Reaction-Induced in Situ Metallic Fusion.

Kang S, Nam D, Choi J, Ko J, Kim D, Kwon CH, Huh J, Cho J.

ACS Appl Mater Interfaces. 2019 Mar 27;11(12):12032-12042. doi: 10.1021/acsami.8b21445. Epub 2019 Mar 18.

PMID:
30883078
15.

The Therapeutic Implications of the Gut Microbiome and Probiotics in Patients with NAFLD.

Perumpail BJ, Li AA, John N, Sallam S, Shah ND, Kwong W, Cholankeril G, Kim D, Ahmed A.

Diseases. 2019 Feb 25;7(1). pii: E27. doi: 10.3390/diseases7010027. Review.

16.

Lysophosphatidic acid increases mesangial cell proliferation in models of diabetic nephropathy via Rac1/MAPK/KLF5 signaling.

Kim D, Li HY, Lee JH, Oh YS, Jun HS.

Exp Mol Med. 2019 Feb 15;51(2):18. doi: 10.1038/s12276-019-0217-3.

17.

Lysophosphatidic acid receptor 1 inhibitor, AM095, attenuates diabetic nephropathy in mice by downregulation of TLR4/NF-κB signaling and NADPH oxidase.

Lee JH, Sarker MK, Choi H, Shin D, Kim D, Jun HS.

Biochim Biophys Acta Mol Basis Dis. 2019 Jun 1;1865(6):1332-1340. doi: 10.1016/j.bbadis.2019.02.001. Epub 2019 Feb 11.

18.

Protective Effects of Broussonetia kazinoki Siebold Fruit Extract against Palmitate-Induced Lipotoxicity in Mesangial Cells.

Kim D, Kim HJ, Cha SH, Jun HS.

Evid Based Complement Alternat Med. 2019 Jan 8;2019:4509403. doi: 10.1155/2019/4509403. eCollection 2019.

19.

The interaction of nonalcoholic fatty liver disease and smoking on mortality among adults in the United States.

Wijarnpreecha K, Scribani M, Kim D, Kim WR.

Liver Int. 2019 Jan 29. doi: 10.1111/liv.14058. [Epub ahead of print]

PMID:
30697898
20.

Race/ethnicity-based temporal changes in prevalence of NAFLD-related advanced fibrosis in the United States, 2005-2016.

Kim D, Kim W, Adejumo AC, Cholankeril G, Tighe SP, Wong RJ, Gonzalez SA, Harrison SA, Younossi ZM, Ahmed A.

Hepatol Int. 2019 Mar;13(2):205-213. doi: 10.1007/s12072-018-09926-z. Epub 2019 Jan 29.

PMID:
30694445

Supplemental Content

Loading ...
Support Center